We scan new podcasts and send you the top 5 insights daily.
In clinical practice and clinical trial arms planned for nine perioperative cycles of EV-pembrolizumab, most patients fail to complete therapy due to adverse events. Consequently, real-world clinicians already administer de-escalated regimens resembling shorter three-cycle protocols out of necessity.
In real-world practice, oncologists are granting treatment breaks, or 'holidays,' to metastatic bladder cancer patients who achieve major responses on enfortumab vedotin-pembrolizumab. This practice, driven by toxicity management and quality of life concerns, is common despite the lack of formal trial data to guide the optimal duration or timing of discontinuation.
Extrapolating from the metastatic setting, clinicians should anticipate that most patients on the 9-cycle perioperative EV-pembrolizumab regimen will require dose reductions or holds. Cumulative peripheral neuropathy is the primary driver, suggesting a need for proactive, individualized dose management rather than strict adherence to the trial's protocol.
A critical reason patients stop ADC treatments is the burden of side effects like skin toxicity or GI issues, not just disease progression. This underscores the urgent need to develop ADCs with better safety profiles, enabling patients to stay on effective therapy longer.
The practice-changing Keynote B15 trial showed strong efficacy for neoadjuvant EV-Pembro. However, about half of patients discontinued treatment due to side effects. This creates a clinical paradox: patients who complete the full regimen may be over-treated, while those who stop early due to toxicity may be under-treated, complicating patient management and counseling.
Volga demonstrated overall survival benefits using only three neoadjuvant cycles of enfortumab vedotin combined with durvalumab. This finding questions whether patients truly need the extensive nine cycles delivered in Keynote-905, igniting debates over balancing oncologic cure against toxicity and healthcare costs.
Success with shorter, fixed-duration ADC regimens in perioperative bladder cancer trials is prompting oncologists to evolve their thinking in the metastatic setting. The conversation is shifting away from indefinite treatment towards stopping therapy earlier for patients with deep responses.
Remarkable pathologic response rates from just 3-4 cycles of neoadjuvant EV-Pembro are creating divergent research questions. Future trials will explore whether some patients could benefit from more cycles (escalation) while high-responders might be able to skip cystectomy entirely (de-escalation).
New bladder-sparing trials mandate nine cycles of EV-Pembro to replicate the conditions of successful surgical trials. This conservative approach ignores that patient response is front-loaded while toxicity is back-loaded, likely overtreating many patients to ensure comparable efficacy.
A key lesson in bladder cancer is that patient attrition is rapid between lines of therapy; many who relapse from localized disease never receive effective later-line treatments. This reality provides a strong rationale for moving the most effective therapies, like EV-pembrolizumab, to earlier settings to maximize the number of patients who can benefit.
While the pivotal EV-302 trial allowed for indefinite Enfortumab Vedotin (EV) treatment, real-world clinical experience shows very few patients reach the two-year mark due to cumulative toxicity. This highlights a major divergence between clinical trial design and practical application, with only about 10% making it that long.